Incyte Corp (INCY)

Add to Watchlists
Create an Alert
Quickflows
65.56 -0.22  -0.33% NASDAQ Oct 15, 16:00 65.53 -0.03  -0.05% After-Hours: 20:00 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All INCY News

News

View All Events

Events

Date Type Description
11/02/2021 Earnings Results Q3 2021 Earnings Results
11/02/2021 08:00 EST Earnings Calls Q3 2021 Earnings Call
08/03/2021 Earnings Results Q2 2021 Earnings Results
08/03/2021 08:00 EST Earnings Calls Q2 2021 Earnings Call
05/26/2021 07:00 EST AGM 2020 Annual General Meeting
05/04/2021 Earnings Results Q1 2021 Earnings Results
05/04/2021 08:00 EST Earnings Calls Q1 2021 Earnings Call
02/09/2021 Earnings Results Q4 2020 Earnings Results
02/09/2021 08:00 EST Earnings Calls Q4 2020 Earnings Call
11/05/2020 Earnings Results Q3 2020 Earnings Results
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 2.721B
Total Expenses (TTM) 2.291B
Net Income (TTM) 337.64M

Balance Sheet View Statement

Total Assets (Quarterly) 3.905B
Total Liabilities (Quarterly) 968.76M
Shareholders Equity (Quarterly) 2.936B

Cash Flow Statement View Statement

Cash from Operations (TTM) 668.48M
Cash from Investing (TTM) -226.08M
Cash from Financing (TTM) 29.32M

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). Incyte's pipeline includes a broad array of oncology and dermatology programs.
  • URL: https://www.incyte.com
  • Investor Relations URL: https://investor.incyte.com/investors/default.aspx
  • HQ State/Province: Delaware
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Nov. 02, 2021
  • Last Earnings Release: Aug. 03, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 65.56
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
PBE Invesco Dynamic Biotech & Genome ETF 4.47%
FBT First Trust NYSE Arca Biotech ETF 2.80%
ARKG ARK Genomic Revolution ETF 2.61%
TAGFX Transamerica Mid Cap Growth R6 2.54%
CAMUX Cambiar SMID Institutional 2.54%
CCGSX Chautauqua Global Growth Investor 2.48%
BBH VanEck Biotech ETF 1.94%
TDB3016 TD Health Sciences - D (USD) 1.71%
VGHCX Vanguard Health Care Inv 1.47%
THISX T. Rowe Price Health Sciences I 1.15%
BIB ProShares Ultra Nasdaq Biotechnology 1.14%
IBB iShares Biotechnology ETF 1.14%

Comparables

Edit
LLY Eli Lilly and Co
SNDX Syndax Pharmaceuticals Inc
BIIB Biogen Inc
PFE Pfizer Inc
ABBV AbbVie Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.